首页> 美国卫生研究院文献>Blood Advances >Handling challenging questions in the management of chronic myeloid leukemia: when is it safe to stop tyrosine kinase inhibitors?

【2h】

Handling challenging questions in the management of chronic myeloid leukemia: when is it safe to stop tyrosine kinase inhibitors?

机译：在慢性骨髓白血病管理中处理挑战性问题：停止止动酪氨酸激酶抑制剂是安全的吗？

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

The paradigm for managing patients with chronic myeloid leukemia is evolving. In the recent past, restoring a normal life expectancy while patients are receiving never-ending targeted therapy with BCR–ABL1 tyrosine kinase inhibitors through prevention of progression to blast phase and mitigation of iatrogenic risks was considered the best achievable outcome. Now, long-term treatment-free remission with continued response off tyrosine kinase inhibitor therapy is recognized as the most optimal benefit of treatment. Indeed, numerous independent clinical trials provided solid proof that tyrosine kinase inhibitor discontinuation was feasible in patients with deep and sustained molecular responses. This article discusses when tyrosine kinase inhibitors may be safely stopped in clinical practice on the basis of the best and latest available evidence.

机译：管理慢性骨髓白血病患者的范式正在不断发展。在最近的过去，恢复正常的预期寿命，而患者通过预防进展来接受与BCR-ABL1酪氨酸激酶抑制剂免疫靶向治疗，并且对爆炸阶段的进展和对性病风险的减轻被认为是最佳的可实现的结果。现在，随着酪氨酸激酶抑制剂治疗的持续反应的长期治疗缓解被认为是治疗的最佳益处。实际上，许多独立的临床试验提供了坚实的证据，即酪氨酸激酶抑制剂停药在深度和持续的分子反应的患者中是可行的。本文讨论了酪氨酸激酶抑制剂的基础上可以在最佳和最新的可用证据的基础上安全地停止在临床实践中。

著录项

期刊名称 Blood Advances
作者
Delphine Rea;
展开▼
作者单位

展开▼
年(卷),期 2020(4),21
年度 2020
页码 5589–5594
总页数 6
原文格式 PDF
正文语种
中图分类心血管疾病;
关键词

相似文献

外文文献
中文文献
专利

1. Handling challenging questions in the management of chronic myeloid leukemia: when is it safe to stop tyrosine kinase inhibitors? [J] . Delphine Rea Hematology . 2020,第1期

机译：在慢性骨髓白血病管理中处理挑战性问题：停止止动酪氨酸激酶抑制剂是安全的吗？
2. Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid Leukemia Activity of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in the Blast Crisis of Chronic Myeloid Leukemia and Acute Lympoblastic Leukemia wit [J] . B. J. Druker, M. Talpaz, D. J. Resta, Chemtracts . 2001,第13期

机译：BCR-ABL酪氨酸激酶特异性抑制剂在慢性粒细胞白血病中的功效和安全性BCR-ABL酪氨酸激酶特异性抑制剂在慢性粒细胞白血病和急性淋巴细胞白血病机智的爆发危机中的活性
3. Pattern of Use and Long-Term Safety of Tyrosine Kinase Inhibitors: A Decade of Real-World Management of Chronic Myeloid Leukemia [J] . Bettiol Alessandra, Marconi Ettore, Lombardi Niccolo, Clinical drug investigation . 2018,第9期

机译：酪氨酸激酶抑制剂的使用模式和长期安全性：慢性骨髓白血病的真实世界管理十年
4. Novel Inhibitors of T315I Mutant BCR-ABL1 Tyrosine Kinase for Chronic Myeloid Leukemia Disease Through Fragment-Based Drug Design [C] . Satya Anindita, Atika Marnolia, Hersal Hermana Putra, International symposium on bioinformatics research and applications . 2018

机译：T315I突变BCR-ABL1酪氨酸激酶的新型抑制剂通过基于片段的药物设计治疗慢性粒细胞白血病
5. The multi-targeted receptor tyrosine kinase inhibitor, linifanib (ABT-869), induces apoptosis and inhibits proliferation of leukemia cells through phosphoinositide-3 kinase (PI3K)/AKT-dependent signaling pathways. [D] . Hernandez, Jenny Elizabeth. 2010

机译：多靶点受体酪氨酸激酶抑制剂利尼法尼（ABT-869）通过磷酸肌醇3激酶（PI3K）/ AKT依赖性信号传导途径诱导凋亡并抑制白血病细胞的增殖。
6. Handling challenging questions in the management of chronic myeloid leukemia: when is it safe to stop tyrosine kinase inhibitors? [O] . Delphine Rea 2020

机译：在慢性骨髓白血病管理中处理挑战性问题：停止止动酪氨酸激酶抑制剂是安全的吗？
7. Handling challenging questions in the management of chronic myeloid leukemia: when is it safe to stop tyrosine kinase inhibitors? [O] . Delphine Rea 2020

机译：在慢性骨髓白血病管理中处理挑战性问题：停止止动酪氨酸激酶抑制剂是安全的吗？

Handling challenging questions in the management of chronic myeloid leukemia: when is it safe to stop tyrosine kinase inhibitors?

摘要

著录项

相似文献

相关主题

期刊订阅